

FOI 3618

10th March 2026**FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

Q1. How many patients has your Trust treated in the past 12 months (February 2025 - January 2026, or latest 12 months available) for Mantle Cell Lymphoma (MCL) (excluding patients being monitored but not undergoing active treatment)? In case you do not treat MCL, which other Trust do you refer patients needing treatment to?

Q2. How many Mantle Cell Lymphoma (MCL) patients have been treated by the Trust in the past 6 months (August 2025 - January 2026, or latest 6 months available) on the following treatments:

- **BR (Bendamustine + rituximab)**
- **VR-CAP (Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide and prednisolone)**
- **R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone)**
- **R-maxi-CHOP or Nordic Protocol (R-CHOP alternated with Rituximab+ High-dose Cytarabine)**
- **CVP (cyclophosphamide, vincristine and prednisolone)**
- **Brukinsa (zanubrutinib)**
- **Imbruvica (ibrutinib)**
- **Velcade (bortezomib) + chemotherapy**
- **Tecartus (brexucabtegene autoleucel)**
- **R-BAC (rituximab, bendamustine and cytarabine)**
- **R-DHAP (rituximab + cytarabine + cisplatin + dexamethasone)**
- **Any other systemic anti-cancer therapy**
- **Wait and watch (monitoring only, no active treatment)**

- **Q3. How many Mantle Cell Lymphoma (MCL) new patients have been initiated by the Trust in the past 6 months (August 2025 - January 2026, or latest 6 months available) on the following treatments:**

For this question, please only count patients that have received the below treatments for the first time.

- **BR (Bendamustine + rituximab)**
- **VR-CAP (Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide and prednisolone)**
- **R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone)**
- **R-maxi-CHOP or Nordic Protocol (R-CHOP alternated with Rituximab+ High-dose Cytarabine)**
- **CVP (cyclophosphamide, vincristine and prednisolone)**
- **Brukinsa (zanubrutinib)**
- **Imbruvica (ibrutinib)**
- **Velcade (bortezomib) + chemotherapy**
- **Tecartus (CAR-T)**
- **R-BAC (rituximab, bendamustine and cytarabine)**
- **R-DHAP (rituximab + cytarabine + cisplatin + dexamethasone)**
- **Any other systemic anti-cancer therapy**
- **Wait and watch (monitoring only, no active treatment)**

Q4. If your Trust does treat Mantle Cell Lymphoma (MCL) patients, do you currently participate in any ongoing clinical trials for the treatment of MCL? If yes, please can you provide details of the ongoing trials.

Response to Questions 1-4:

There is no data available from pharmacy sources as Haematological chemotherapy is not prescribed through an electronic system that links the drugs prescribed to the diagnosed disease condition.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

This information is not recorded centrally and therefore retrieving it would involve a manual search of individual patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.



Southern Health
and Social Care Trust

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of individual patient charts just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Email: Foi.Team@Southerntrust.hscni.net